Boehringer backs T3 to take bacterial cancer therapy into clinic

T3 Pharmaceuticals has raised CHF 25 million ($27 million) to take its lead bacterial cancer therapy into the clinic. Boehringer Ingelheim Venture Fund (BIVF) co-led the round with the support of other existing investors.